- Home
- ENPH vs CRNX Comparison
ENPH vs CRNX Comparison
Compare ENPH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | CRNX |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ENPH | CRNX |
|---|---|---|
| Price | $31.66 | $48.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 11 |
| Target Price | $42.02 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 6.7M | 1.3M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.44 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $1,512,377,000.00 | $1,535,000.00 |
| Revenue This Year | $12.30 | $425.31 |
| Revenue Next Year | N/A | $943.50 |
| P/E Ratio | $21.89 | ★ N/A |
| Revenue Growth | 20.97 | ★ 47.74 |
| 52 Week Low | $25.78 | $24.10 |
| 52 Week High | $78.26 | $60.34 |
Technical Indicators
Market Signals| Indicator | ENPH | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 65.94 |
| Support Level | $26.42 | $46.49 |
| Resistance Level | $32.60 | $49.29 |
| Average True Range (ATR) | 1.29 | 2.06 |
| MACD | 0.69 | 0.29 |
| Stochastic Oscillator | 84.14 | 85.74 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.